Search details
1.
Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).
Oncologist
; 29(3): e330-e336, 2024 Mar 04.
Article
in English
| MEDLINE | ID: mdl-37950903
2.
Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.
Int J Clin Oncol
; 29(1): 27-35, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37964066
3.
Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.
Int J Clin Oncol
; 29(6): 764-770, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38555323
4.
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study.
Esophagus
; 2024 Apr 12.
Article
in English
| MEDLINE | ID: mdl-38607538
5.
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Oncologist
; 28(11): e1108-e1113, 2023 Nov 02.
Article
in English
| MEDLINE | ID: mdl-37284901
6.
Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
BMC Cancer
; 23(1): 726, 2023 Aug 05.
Article
in English
| MEDLINE | ID: mdl-37543568
7.
The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer.
Future Oncol
; 19(17): 1165-1174, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-37458152
8.
Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study.
Int J Clin Oncol
; 28(6): 756-763, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-36943545
9.
Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center.
Int J Clin Oncol
; 28(5): 644-653, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36899286
10.
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant.
Int J Clin Oncol
; 28(5): 654-663, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36856908
11.
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
JAMA
; 329(15): 1271-1282, 2023 04 18.
Article
in English
| MEDLINE | ID: mdl-37071094
12.
[Discrepancy in Gastric Cancer Chemotherapy between the Asia and West].
Gan To Kagaku Ryoho
; 50(1): 23-29, 2023 Jan.
Article
in Japanese
| MEDLINE | ID: mdl-36759981
13.
The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma.
Esophagus
; 20(3): 524-532, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36595124
14.
Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma.
Esophagus
; 20(3): 533-540, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36750480
15.
Comprehensive registry of esophageal cancer in Japan, 2015.
Esophagus
; 20(1): 1-28, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36152081
16.
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
Gut
; 71(7): 1277-1288, 2022 07.
Article
in English
| MEDLINE | ID: mdl-34433583
17.
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.
Lancet Oncol
; 23(1): 115-124, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34919824
18.
A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.
Cancer
; 128(10): 2025-2035, 2022 05 15.
Article
in English
| MEDLINE | ID: mdl-35195274
19.
Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study.
Gastric Cancer
; 25(1): 245-253, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34581902
20.
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer.
Gastric Cancer
; 25(3): 619-628, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35254550